GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLA) » Definitions » Insider Ownership

Estrella Immunopharma (Estrella Immunopharma) Insider Ownership : 1.53 % (As of Jun. 02, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Estrella Immunopharma's insider ownership is 1.53%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Estrella Immunopharma's Institutional Ownership is 0.21%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Estrella Immunopharma's Float Percentage Of Total Shares Outstanding is 0.00%.


Estrella Immunopharma Insider Ownership Historical Data

The historical data trend for Estrella Immunopharma's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma Insider Ownership Chart

Estrella Immunopharma Historical Data

The historical data trend for Estrella Immunopharma can be seen below:

2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Insider Ownership 1.60 1.60 1.60 1.60 1.53 1.53 1.53

Estrella Immunopharma Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Estrella Immunopharma (Estrella Immunopharma) Business Description

Traded in Other Exchanges
N/A
Address
5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608
Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma (Estrella Immunopharma) Headlines

No Headlines